ARTICLE | Company News
Intercell, Merck deal
May 15, 2006 7:00 AM UTC
MRK exercised an option under a 2004 deal with ICLL to license worldwide rights to develop and commercialize human MAbs to treat severe S. aureus infections. The antibodies are directed against antige...